IGF2BP2 Antibody (YA2033)(PBS only)

Cat. No.: HY-P82288A: Data Sheet User Guide for Antibodies
FAQs
Technical Support

IGF2BP2 Antibody (YA2033) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IGF2BP2.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

IGF2BP2 Antibody (YA2033) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IGF2BP2.

Host

Rabbit

Molecular Weight

Predicted band size: 66 kDa;

Observed band size: 66,62 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Mouse, Rat

SwissProt ID

Q9Y6M1

Gene ID

10644 [NCBI]

Immunogen

A synthesized peptide derived from human IMP2

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-1:1000
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:50-1:100
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:50-1:200

Purity	Affinity Purified	Conjugation	Non-conjugated
Isotype	IgG

Appearance

Liquid

Formulation

Supplied in PBS, pH 7.4.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：RNA-binding factor that recruits target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation (By similarity). Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed:29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs (PubMed:9891060). Binding is isoform-specific. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed:29476152)

Subcellular Localization：Nucleus; Cytoplasm; Cytoplasm, P-body; Cytoplasm, Stress granule

Expression：
Tissue_specificity:Expressed in oocytes, granulosa cells of small and growing follicles, Leydig cells, spermatogonia and semen (at protein level) . Expressed in testicular cancer (at protein level) . Expressed weakly in heart, placenta, skeletal muscle, bone marrow, colon, kidney, salivary glands, testis and pancreas. Detected in fetal liver, fetal ovary, gonocytes and interstitial cells of the testis

Isoforms & Post-Translational Modification：Q9Y6M1 has 6 isomers: Q9Y6M1-2: 66121 Da (predicted); Q9Y6M1-1: 61842 Da (predicted); Q9Y6M1-3: 59001 Da (predicted); Q9Y6M1-4: 59666 Da (predicted); Q9Y6M1-5: 54722 Da (predicted); Q9Y6M1-6: 58578 Da (predicted).

Subunit：Can form homooligomers and heterooligomers with IGF2BP1 and IGF2BP3 in an RNA-dependent manner (PubMed:23640942). Interacts with HNRPD (PubMed:12674497). Interacts with IGF2BP1 (PubMed:17289661). Interacts with ELAVL1, DHX9, HNRNPU, MATR3 and PABPC1 (PubMed:23640942, PubMed:29476152). Interacts with the HOXB-AS3 peptide; the interaction increases MYC stability (PubMed:34457052)

Research Field

Epigenetics and Nuclear Signaling

Synonyms

IGF2BP2; IMP2; VICKZ2; Insulin-like growth factor 2 mRNA-binding protein 2; IGF2 mRNA-binding protein 2; IMP-2; Hepatocellular carcinoma autoantigen p62; IGF-II mRNA-binding protein 2; VICKZ family member 2

Documentation

User Guide for Antibodies (1077 KB)